MN rgp120/HIV-1 and A244 rgp120/HIV-1

BIOLOGICAL4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), VaxGen

Conditions

HIV InfectionsHIV Seronegativity

Phase 1

A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines

CompletedNCT00002402

VaxGenHIV Infections

Target: 120Updated: 2005-06-24

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

CompletedNCT00001096

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2000-03-31Target: 60Updated: 2021-11-04

Phase 2

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

CompletedNCT00000871

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2000-01-31Target: 420Updated: 2021-11-04

Phase 3

Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand

CompletedNCT00006327

VaxGenHIV Infections, HIV Seronegativity

Start: 1999-03-31End: 2000-08-31Target: 2500Updated: 2005-06-24

Related Papers

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.

2022-06-0134 citations